Home/Pipeline/Tiragolumab + Tecentriq

Tiragolumab + Tecentriq

Non-Small Cell Lung Cancer (NSCLC)

Phase IIIActive

Key Facts

Indication

Non-Small Cell Lung Cancer (NSCLC)

Phase

Phase III

Status

Active

Company

Roche

About Roche

Roche is a global healthcare leader with a unique dual-pillar strategy combining its Pharmaceuticals and Diagnostics divisions to address the full patient journey. Under CEO Thomas Schinecker, the company focuses on preventing disease through early identification, halting progression via targeted therapies, and restoring health with curative medicines. With a market cap of ~$256B, it leverages its integrated platform to drive innovation in oncology, neurology, immunology, and infectious diseases, while pursuing sustainable, long-term growth.

View full company profile

Therapeutic Areas

Oncology Neurology Immunology Infectious Diseases Ophthalmology Rare Diseases

Other Non-Small Cell Lung Cancer (NSCLC) Drugs

Drug	Company	Phase	Status
LW-02 Immunopheresis	Immunicom	Phase 2	Active
Idylla EGFR Mutation Assay	Biocartis	Approved	CE-IVD
ABD-3001	Advanced Biodesign	Phase 1	Active
Macrocyclic OMNI-EGFR Inhibitor	BlossomHill Therapeutics	Phase 1	Active
TUMORIN Clinical Trial	Nilogen Oncosystems	N/A (Diagnostic Validation)	Active
Membrex™	Metaclipse Therapeutics	Pre-clinical	Active
Lazertinib (Leclaza)	Genosco	Approved	Active
IPH5201 (anti-CD39 mAb)	Orega Biotech	Phase 2	Active
Platin-DRP®	Chosa Oncology	Validation	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Aspyre Clinical Test for Lung	Biofidelity	Commercial	Active
EGFR Mutation Detection Assay	Stilla Technologies	Assay Development/Validation	Active